Celera Corporation

Summit Therapeutics Appoints Dr. Robert Booth, Renowned Executive and Scientific Leader, to its Board of Directors

Retrieved on: 
Monday, October 3, 2022
Virobay, Ridinilazole, Inflammation, BTK, GLOBE, Doctor of Philosophy, Stanford University School of Medicine, NASDAQ, Risk, Research, Knowledge, Clinical trial, Genomics, Drug discovery, Food, Private Securities Litigation Reform Act, CEO, Health, Hoffmann-La Roche, COVID-19, Goal, Coronavirus, University, U.S. Securities and Exchange Commission, Team, Therapy, Quality of life, Nasdaq, Autoimmune disease, Executive, Leadership, Security (finance), Patient, Hematological Cancer Research Investment and Education Act, Trauma, Celera Corporation, Food and Drug Administration Amendments Act of 2007, Character, Board of directors, Biochemistry, SMMT, Board, Marketing, Company, Medical device, Pharmaceutical industry, Management, Safety, Pharmacyclics

Menlo Park, California, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Robert Booth, PhD,has been appointed to its Board of Directors, effective immediately.

Key Points: 
  • Menlo Park, California, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Robert Booth, PhD,has been appointed to its Board of Directors, effective immediately.
  • He has over 30 years of experience in the biopharmaceutical industry from executive positions to research and scientific leadership primarily focusing in the areas of oncology, inflammation, and autoimmune disease.
  • He is the co-founder of CuraSen Therapeutics, Inc. where he was previously the Executive Chairman and currently serves as an advisor.
  • Dr. Booth currently serves on the board of Thryv Therapeutics Inc.; he previously served on the boards of Pharmacyclics, Inc., and CymaBay Inc.

Septerna Strengthens Leadership Team to Advance Novel Small Molecule GPCR Medicines

Retrieved on: 
Thursday, July 28, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, University of California, San Diego, Strategic planning, Norwest Venture Partners, Northwestern University, Illinois Institute of Technology, Chemistry, Cell membrane, G protein-coupled receptor, Corporation, Ambi Pur, University, Corporate development, Celera Corporation, GPCR, Kellogg School, Protein, Human, Doctor of Philosophy, Third Rock Ventures, CV, Commercial, VP, Research, Drug discovery, BA, BS, Institute of Chartered Financial Analysts of India, Therapy, Family, Eli Lilly, Shanghai University of Finance and Economics, MS, MBA, AMT, MD, Gilead Sciences, Patient, Business operations, Market for corporate control, Growth, Maxygen, SVKM's NMIMS, Economics, Pharmaceutical industry, Management, Fine chemical, Pomona College, Technology

Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced the addition of Liz Bhatt, MS, MBA, as Chief Operating Officer, and Ran Xiao as Vice President of Finance and Business Operations to its leadership team.

Key Points: 
  • Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced the addition of Liz Bhatt, MS, MBA, as Chief Operating Officer, and Ran Xiao as Vice President of Finance and Business Operations to its leadership team.
  • Septerna launched in January 2022 and is growing a pipeline of differentiated products using its GPCR Native Complex platform to unlock the vast untapped potential of GPCR drug targets for a wide range of diseases.
  • Septerna has an emerging pipeline of GPCR-targeted small molecule drug discovery programs, along with growth potential to reach many GPCRs that have been undruggable and unexploited to date.
  • Septerna was launched in 2022 by scientific founders who have made groundbreaking GPCR discoveries and by founding investor Third Rock Ventures.

Nkarta Announces Key Senior Leadership Team Appointments

Retrieved on: 
Monday, July 25, 2022
San Francisco State University, Sale, Certified Public Accountant, University, GLOBE, National Taiwan Normal University, Celera Corporation, University of Basel, Treasury, U.S. Securities and Exchange Commission, Doctor of Philosophy, American Institute, CEO, SEC, CAR, Howard Hughes Medical Institute, Intellectual property, Vienna Biocenter, Compliance, Private Securities Litigation Reform Act, American Institute of Certified Public Accountants, Risk, COVID-19, Baxter International, CRISPR, Cancer, Leadership, University of California, San Francisco, MS, MBA, Cryopreservation, Senior, Security (finance), Patient, OncoMed, NK, Biology, Cell biology, Accounting, Growth, Financial management, Pharmaceutical industry, Management

Ralph and Yvonne have each distinguished themselves through their exceptional accomplishments, leadership of collaborative teams and valuable cross-functional contributions to Nkarta, said Paul J. Hastings, President and CEO of Nkarta.

Key Points: 
  • Ralph and Yvonne have each distinguished themselves through their exceptional accomplishments, leadership of collaborative teams and valuable cross-functional contributions to Nkarta, said Paul J. Hastings, President and CEO of Nkarta.
  • Dr. Brandenberger joined Nkarta in April 2018 and most recently served as Senior Vice President, Technical Operations.
  • Ms. Li joined Nkarta in November 2019 as Senior Vice President, Finance to lead the companys financial management, treasury, tax, accounting, and SEC reporting operations.
  • Prior to joining Nkarta, she held senior leadership roles in finance, accounting and operations at Amunix and OncoMed.

Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer

Retrieved on: 
Monday, June 27, 2022
Technology, Other Technology, Health Technology, Stem Cells, Software, Biotechnology, Health, Pharmaceutical, Artificial Intelligence, Patient, Biotechnology, Technology, Senior, Therapy, Engineering, BCEL, Bionics, Development, Abhi, Syntex, Boston, Physics, Corporate development, SVP, Hoffmann-La Roche, MIT, Bose Corporation, Doctor of Philosophy, Neuromodulation, Celera Corporation, Quest Diagnostics, NASDAQ, Biomedical engineering, Amgen, Twitter, Paulette, Global, Pfizer, Management, Pharmaceutical industry, Anacor, Medtronic, Electronics, Exelixis, Research, Cellino

Cellino Biotech, Inc. , an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Senior Vice President (SVP) and Chief Business Officer.

Key Points: 
  • Cellino Biotech, Inc. , an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Senior Vice President (SVP) and Chief Business Officer.
  • We are delighted to welcome Abhi and Paulette, who bring invaluable expertise in advanced technology development and business to Cellino, said Nabiha Saklayen, Ph.D., Chief Executive Officer & Co-Founder, Cellino.
  • Abhi brings over 25 years of experience working on innovative solutions spanning the disciplines of neuroscience, engineering, and physics.
  • Prior to joining Cellino, she was Senior Vice President of Corporate Development and Co-Founder of Atreca, Inc., (NASDAQ: BCEL) a public biopharmaceutical antibody-based company.

ZeroAvia & Otto Aviation Partner to Deliver First New Airframe Design with Hydrogen-Electric Engine Option

Retrieved on: 
Wednesday, June 15, 2022
Hydrogen, Zero, Climate change, Department, Water, NOx, Aircraft, Carbon, FAA, Technology, BEIS, CEO, Department for Business, Energy and Industrial Strategy, ATI, Efficiency, Business, Aviation, LLC, Defence Industrial Strategy, LinkedIn, Innovation, Sulfur oxide, Founder CEO, Electricity, Maintenance, Innovate UK, Partnership, Twitter, Project, Transport, CAA, Multimedia, Instagram, D, ZeroAvia, Otto's, Original equipment manufacturer, Climate, UK Government Decontamination Service, Diesel fuel, Airline, Celera Corporation

HOLLISTER, Calif. and KEMBLE, England, June 15, 2022 /PRNewswire/ -- ZeroAvia, the leader in hydrogen-electric solutions for aviation, today announced a collaboration with Otto Aviation, LLC, to develop a hydrogen-electric powertrain to power Otto's Celera aircraft.

Key Points: 
  • Under the agreement, Otto and ZeroAvia will work to integrate ZeroAvia's ZA600 zero-emission engines to Otto's revolutionary Celera aircraft.
  • The collaboration has the potential to make the Celera the first new airframe design to leverage zero-emission propulsion in its launch models.
  • Announcing the partnership today, William Otto, CEO of Otto Aviation, said: "ZeroAvia's hydrogen-electric powertrain helps us to realize the commitment Otto has made to lower operating costs and climate impact for operators.
  • However, efficiency gains from new airframe design can expand the impact of zero-emission aviation.

Seceon Wins Global Infosec 2022 Awards at RSA, Continues the Sales Momentum in Q2 and Hires Key Sales Executives

Retrieved on: 
Wednesday, June 8, 2022
VP, GDPR, Applied Biosystems, Linde plc, OTM, Conference, WEVO, AGC, CDM, NTA, TI, Twitter, Computer security, Genomics, Risk assessment, RSA, Product management, AI, CEO, Windows IoT, NBAD, Telemetry, Architecture, SIEM, Infrastructure as a service, MSSP, SOAR, Solution, Telecommunication, Intelligence, EDR, Industry, CMMC, Efficiency, Celera Corporation, ExaGrid, SOC, CISO, Health, Software as a service, ROI, CERT, Platform as a service, ML, Risk management

WESTFORD, Mass, June 8, 2022 /PRNewswire/ -- Seceon, the pioneer of the first fully-automated, real-time cyber threat detection, containment and elimination platform to empower Enterprises and MSSPs with its award-winning solutions (#aiSIEM, #aiMSSP, #aiXDR), announced that it has won following Awards at RSA Conference 2022 from Cyber Défense Magazine (CDM).

Key Points: 
  • Seceon also hired two seasoned cybersecurity professionals in finance, healthcare and telecommunications industry.
  • Previously, Paul worked as director of inside sales at ExaGrid, where he helped consistently deliver record growth over 5 years.
  • Seceon empowers Enterprises and MSSPs to provide "Comprehensive Cybersecurity for the Digital-Era".
  • To learn more, please visit: www.seceon.com or email [email protected] or call (978) 923-0040 and follow the company on: Twitter | Facebook | LinkedIn

Chemical Marketing & Economics (CME) to Honor Air Products' Chairman, President and CEO Seifi Ghasemi with CME STEM Leadership Award™ for Lifetime Achievement

Retrieved on: 
Wednesday, April 27, 2022
Solution, Chemical industry, LinkedIn, Natural Resources, Metropolitan Club, Electronics, Association, The Business Council, Keynote, BASF, Mathematics, Transport, Facebook, List of Nobel laureates, MIT, Lafayette College, Industry, Air Products & Chemicals, Instagram, DuPont, NYSE, Director, Leadership, GKN, Food, Company, Motherboard, STEM, Carbon, Plant, BOC (company), Hydrogen, HLI, Celera Corporation, BOC Group, Twitter, KKR, Metal, International Palladium Medal, Board, Government, List of lifetime achievement awards, CME, Simons Foundation, Merck, Chemistry, NASA, Metropolitan, Stevens Institute of Technology, Honeywell, Stanford University, Environment, Culture, Management, Renewable energy, Pharmaceutical industry, Science, Mars, Technology, Smithsonian Institution, Engineering

BRANCHBURG, N.J. and LEHIGH VALLEY, Pa., April 27, 2022 /PRNewswire/ -- Chemical Marketing & Economics, Inc. (CME) and Air Products (NYSE: APD) today announced that Seifi Ghasemi, chairman, president and chief executive officer at Air Products, will be the recipient of the CME STEM Leadership Award™ for Lifetime Achievement. Mr. Ghasemi will be honored at a reception and gala on December 7, 2022, at the Metropolitan Club in New York City. The Keynote will be NASA Chief Scientist Katherine Calvin and the Event Co-Chair will be thyssenkrupp nucera Deputy CEO and COO Daniel Krude.

Key Points: 
  • BRANCHBURG, N.J. and LEHIGH VALLEY, Pa., April 27, 2022 /PRNewswire/ -- Chemical Marketing & Economics, Inc. (CME)and Air Products (NYSE: APD) today announced that Seifi Ghasemi , chairman, president and chief executive officer at Air Products, will be the recipient of the CME STEM Leadership Award for Lifetime Achievement.
  • In December 2022, CME will bestow its prestigious Lifetime Achievement award, reflecting Mr. Ghasemi's visionary leadership at Air Products and his decades-long career running highly successful companies.
  • His dedication enables the next generation of STEM professionals to participate in the company's success," CME Co-Chair Ms. Ksenia Takhistova noted.
  • "When you are in the business world for decades, a few things become crystal clear," said Mr. Ghasemi.

Perspective Group Announcing the Formation of an Advisory Board

Retrieved on: 
Monday, April 25, 2022
Research, Marketing, Advertising, Communications, Biotechnology, Health, Pharmaceutical, General Health, Science, Board, Expedia Group, INSEAD, Human resource management, Corporation, Travel, Vertex, BA, Sidley, Sarepta Therapeutics, Research, GV, Gillette, UCSF, Vertex Pharmaceuticals, Yale University, JD, Biogen, Third Rock Ventures, Creativity, Leadership, Information technology, General counsel, Compliance, University School, Amgen, Johnson & Johnson, Director, Environment, Carroll School of Management, Human resources, Northwestern University Pritzker School of Law, Agios Pharmaceuticals, Industry, University, Acquisition, Sidley Austin, Health, University of California, San Francisco, Senior, Partner (business rank), Therapy, Atlas Venture, Management, Pharmaceutical industry, Medicine, Biology, Boston College, Genentech, Celera Corporation

As strategic advisors, Andrea, Melissa, and Ty will provide Perspective Group and, by proxy its clients, first-hand, market-driven knowledge and expertise in strategic and operational leadership, executive talent acquisition/retention and trends in new company formation.

Key Points: 
  • As strategic advisors, Andrea, Melissa, and Ty will provide Perspective Group and, by proxy its clients, first-hand, market-driven knowledge and expertise in strategic and operational leadership, executive talent acquisition/retention and trends in new company formation.
  • This advisory board further differentiates Perspective Group in enhancing its ability to provide its clients a thoughtful and tailored approach to its core services of C-suite, executive and board search.
  • Perspective Group is a leader in providing board and c-level executive search and advisory services to the biotechnology industry.
  • Perspective Group is a boutique executive search firm specializing in the biotechnology industry.

Scorpion Therapeutics Announces Appointment of Brian Piper as Chief Financial Officer

Retrieved on: 
Monday, November 22, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Patient, Precision, Proteomics, Biology, Cancer, Celera Corporation, University, Biotechnology, Notre Dame, Otsuka Pharmaceutical, Piper, History of the University of Maryland, College Park, Therapy, Drug development, Growth, Shire (pharmaceutical company), Investor relations, Computational chemistry, Pharmaceutical industry, Management

Scorpion Therapeutics, Inc. (Scorpion), a next-generation oncology company whose goal is to develop best- and first-in-class precision medicines for people with cancer, today announced the appointment of Brian Piper as the companys first Chief Financial Officer.

Key Points: 
  • Scorpion Therapeutics, Inc. (Scorpion), a next-generation oncology company whose goal is to develop best- and first-in-class precision medicines for people with cancer, today announced the appointment of Brian Piper as the companys first Chief Financial Officer.
  • We are pleased to welcome Brian to the executive team, said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion.
  • Mr. Piper is a veteran biotech financial executive with over 25 years of experience, including serving as chief financial officer at two publicly traded biotech companies.
  • Prior to Scorpion, he served as Chief Financial Officer at Prelude Therapeutics, where he helped lead the company through a successful initial public offering in 2020 and an underwritten follow-on offering in early 2021.

Chemical Marketing & Economics, Inc. 2021 CME STEM Leadership Awards™ to Honor Business Leaders and Champions of Sustainable Innovation

Retrieved on: 
Monday, October 25, 2021
Air Products & Chemicals, Access Industries, Science, NASA, Honeywell, STEM, KKR, Leadership, Industry, Merck, Economics, Simons Foundation, Government, List of Nobel laureates, Ninth, Symposia, Keynote, CEO, Board, BASF, Regeneron Pharmaceuticals, Metropolitan Club, LyondellBasell, DuPont, CME, Celera Corporation, Iron ore, Pharmaceutical industry

NEW YORK, Oct. 25, 2021 /PRNewswire/ -- The Ninth CME STEM Leadership Awards Luncheon and Gala Reception of Chemical Marketing and Economics, Inc. ("CME") will be held at the New York Metropolitan Club on December 7, 2021, from 11:30 am to 2:30 pm.

Key Points: 
  • NEW YORK, Oct. 25, 2021 /PRNewswire/ -- The Ninth CME STEM Leadership Awards Luncheon and Gala Reception of Chemical Marketing and Economics, Inc. ("CME") will be held at the New York Metropolitan Club on December 7, 2021, from 11:30 am to 2:30 pm.
  • CME will honor Air Products Chairman and CEO Seifi Ghasemi, Carlyle Co-Founder & Chairman Emeritus Daniel D'Aniello, and Merck Chairman Kenneth Frazier.
  • "Propelling the STEM industry leadership for sustainable innovation has been the hallmark of CME activities year-round for over 67 years," said CME Co-Chair Ksenia Takhistova.
  • The CME STEM Leadership Awards honors leaders with distinction in harnessing the transformative power of science to advance humanity.